Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

Enhertu locks onto HER2 receptors – which are found in some breast cancer cells – and can stop them from growing (Daiichi Sankyo, AstraZeneca via AP) Exhausted, with tumours growing in her ...

China’s Duality Biotherapeutics has filed (PDF) paperwork for a Hong Kong IPO, seeking an undisclosed sum to power a broad pipeline of antibody-drug conjugates toward approval. The filing ...